The Global Health Body Issues Concern Over Critical Lack of Obesity Injections

Under 10% of individuals that would benefit from obesity jabs like Wegovy can access them, states the global health agency as it releases its initial recommendations on the therapies.

Considering over a billion individuals worldwide currently obese, it is urging broader and more equitable availability to GLP-1 medication.

According to projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.

"The new guidance acknowledges that excess weight is a lifelong illness that can be addressed with thorough and continuous care," stated the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key barriers to universal availability to the jabs that can aid individuals in losing substantial body mass, notes the agency.

GLP-1 Therapy Scarcity

Even under the present most favorable outlook, the manufacturing of such drugs might only reach about 100 million people – less than 10% of those who need them, according to the WHO.

The guideline encourages countries and companies to widen availability, through strategies including patent sharing.

A patent on semaglutide – the core ingredient of Novo Nordisk's Wegovy – is due to expire in several nations in 2026.

How Obesity Jabs Function

The injections imitate a biological compound to slow digestion, reduce hunger and increase satiety so people consume fewer calories.

People typically start to lose weight in the initial weeks of beginning the once-weekly jabs.

Research points to users may see weight return after a year of stopping the treatment, when their typical hunger resume.

To be overweight or obese raises your likelihood for experiencing medical conditions, such as type 2 diabetes, heart disease, brain attack, and specific malignancies.

Excess weight concerns individuals in all nations and was associated with millions of fatalities worldwide in 2024, according to the health agency.